上海市腫瘤研究所成立于1958年,，1980年被確認為世界衛(wèi)生組織癌癥預防與控制合作中心,。1985年獲批籌建癌基因與相關基因國家重點實驗室,，1987年通過驗收并對外開放,。1996年與上海市科委共建基因治療研究中試上?；?。2003年原上海市衛(wèi)生局與上海交通大學共建上海交通大學腫瘤研究所,。2010年,，與仁濟醫(yī)院實現(xiàn)院所合一,。2019年整建制劃歸上海市教育委員會，由上海交通大學醫(yī)學院和附屬仁濟醫(yī)院共同管理,。
上海市腫瘤研究所擁有實驗室空間約26933平方米,，分別位于三個園區(qū)，其中徐匯園區(qū)7500平方米，浦東園區(qū)新科研樓16433平方米,，閔行園區(qū)上海交通大學閔行校區(qū)3000平方米,。作為癌基因與相關基因國家重點實驗室依托單位，研究所設腫瘤微環(huán)境,、腫瘤分子病理研究組等20個研究組（室）和動物實驗中心,、科學研究公共平臺、《腫瘤》雜志編輯部等輔助部門?，F(xiàn)有在編職工138人,，具有研究生學歷107人，科研人員115人,，其中博士79人,，占68.7%。包括中國工程院院士1人,、國家終身教授1人,。高級職稱專業(yè)技術人員33人，研究生導師29人（博導20人,、碩導9人）,，在讀研究生66人（博士生35人、碩士生31人）,。
研究所致力實施“人才強所”戰(zhàn)略,，先后從國外引入國家特聘專家等一批高水平人才。十三五以來,，有35人次先后入選上海領軍人才,、上海市優(yōu)秀學科帶頭人、上海市科技啟明星計劃,、上海青年科技英才揚帆計劃,、上海市青年拔尖人才開發(fā)計劃、上海市人才發(fā)展資金等人才計劃,。承擔各類縱向科研課題177項（國家級項目59項）,，科研經費達到6545.2萬元。其中,，科技部重大專項課題4項,，國家重點研發(fā)計劃2項，NSFC項目52項,。研制成功全球首個肝癌CAR-T細胞,，臨床試驗療效顯著，在國際實體瘤CAR-T免疫治療研究領域處于領先地位,。CAR-T細胞藥物獲國家藥監(jiān)局注冊臨床研究許可3項,、美國FDA及加拿大衛(wèi)生部臨床試驗許可各1項，在中國、美國等國家和地區(qū)同步開展臨床試驗研究,。以第一單位獲得各類科技成果獎勵3項,，在Nature、Gastroenterology,、Gut等雜志發(fā)表SCI 論文210篇,。授權發(fā)明專利15項，其中1項獲得轉化,，技術轉讓金額106萬元,，推動轉化醫(yī)學研究發(fā)展。
研究所對外交往密切,，先后與美國國立衛(wèi)生研究院（NIH）,、美國國立癌癥研究院（NCI）、耶魯大學,、匹茲堡大學,、范德堡大學、荷蘭癌癥研究所,、韓國首爾大學等20多個國家的一流科研院所建立了合作關系,，聘請了多位國外著名專家和教授擔任顧問，推動雙方學術交流,。
Shanghai Cancer Institute (SCI) was founded in 1958 and was designated as WHO Collaborating Center for Research on Cancer in 1980. In 1985, the establishment of State Key Laboratory of Oncogenes and Related Genes was approved, and the laboratory passed the evaluation and was opened in1987. In 1996, Shanghai Cancer Institute and Shanghai Municipal Commission of Science and Technology set up the Gene Therapy Research Pilot Test Base in Shanghai. In 2003, Shanghai Municipal Public Health Bureau and Shanghai Jiao Tong University (SJTU) set up SJTU Cancer Institute. In 2010, Shanghai Cancer Institute and Renji Hospital were merged into Cancer Center. Shanghai Cancer Institute has been affiliated to Shanghai Municipal Education Commission in 2019 and now the institute is managed by both Shanghai Jiao Tong University School of Medicine and Renji Hospital.
Shanghai Cancer Institute has 26,933 m2 of laboratory space, located in three campuses, including 7,500 m2 in Xuhui campus, 16,433 m2 in the new research building in Pudong campus, and 3,000 m2 in Shanghai Jiao Tong University in Minhang campus. As the host of State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute set up 20 research groups (labs) such as tumor microenvironment and tumor molecular pathology, as well as research support departments such as animal experiment center, core facilities, and editorial department of Tumor Journal. Shanghai Cancer Institute has 138 full-time employees,107 with postgraduate qualifications, 115 scientific researchers, of whom 79 are PhDs, accounting for 68.7%, including 1 CAE academicians and 1 national tenured professor. There are 33 senior professional researchers, 29 graduate student supervisors (20 doctoral supervisors and 9 master supervisors), and 66 graduate students (35 doctoral students and 31 master students).
Since the 13th Five-year Plan, Shanghai Cancer Institute has undertaken 177 scientific research projects (59 national projects) with total scientific research funds of 65.452 million yuan, including 4 National Science and Technology Major Projects of the Ministry of Science and Technology of China, 2 National Key Research and Development Projects, and 52 NSFC projects. Shanghai Cancer Institute has successfully developed the world’s first CAR-T cells for liver cancer therapy with significant clinical trial outcome, making it stay ahead of international CAR-T immunotherapy research. CAR-T cell drugs have obtained 3 clinical research licenses registered by the National Medical Products Administration (NMPA), 1 clinical trial license each from the US FDA and Health Canada, and simultaneously carry out clinical trial research in China and the US. Shanghai Cancer Institute has been awarded 3 Science & Technology Awards and published 210 SCI papers on Nature, Gastroenterology, Gut, and other journals. Shanghai Cancer Institute has obtained 15 invention patents, and 1 of them has been transferred with an amount of over 1.06 million yuan, which has achieved development of translational medicine research.
Shanghai Cancer Institute has maintained frequent exchanges with foreign countries, and has established cooperation with prestigious universities and institutes in more than 20 countries, e.g. National Institutes of Health (NIH), National Cancer Institute (NCI), Yale University, University of Pittsburgh, Vanderbilt University, The Netherlands Cancer Institute, and Seoul National University. Meanwhile, it has hired several foreign famous experts and professors as advisors to promote mutual academic exchange.
